Skip to content
Inciteful Med

Validation & Orientation: Understanding Fabry Disease

Last updated:

Fabry disease is a rare genetic lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme. This causes harmful fatty buildup in cells. While it can cause serious heart and kidney issues, early diagnosis and targeted treatments can successfully stabilize the condition.

Key Takeaways

  • • Fabry disease is a rare genetic disorder where a missing or faulty enzyme causes harmful fatty substances to build up inside cells.
  • • Because early symptoms like pain and fatigue overlap with other common conditions, the disease is frequently misdiagnosed for years.
  • • Women are not merely carriers of the disease and can experience significant symptoms that require medical management.
  • • FDA-approved treatments, including Enzyme Replacement Therapy and oral chaperone therapy, can slow organ damage and improve long-term health.
  • • Managing the disease effectively requires a specialized, multidisciplinary medical team that understands rare genetic disorders.

Receiving a diagnosis of Fabry disease can feel like being dropped into a foreign country without a map. It is normal to feel overwhelmed, anxious, or even relieved to finally have a name for your symptoms. This page is designed to help you find your footing by explaining what is happening in the body and why this condition is often misunderstood.

What is Fabry Disease?

Fabry disease is a lysosomal storage disorder, a group of conditions where the body’s natural recycling system doesn’t work correctly [1]. Inside almost every cell in your body, there are tiny compartments called lysosomes [2]. Think of these as the cell’s “recycling hubs” that break down waste products into reusable parts [3].

In Fabry disease, a specific “recycling tool” called the alpha-galactosidase A (α\alpha-Gal A) enzyme is either missing or not working well [4]. Because this enzyme is faulty, a fatty substance called globotriaosylsphingosine (LysoGb3) begins to build up inside the cells [4][5]. Over time, this buildup causes cellular stress and damage to vital organs like the heart, kidneys, and nervous system [1][6].

Understanding the Rarity

Fabry disease is rare, with an estimated incidence of 1 in 40,000 to 1 in 117,000 people [7][8]. However, experts believe these numbers are significant underestimates [7][9].

There are several reasons why Fabry is often “hidden”:

  • Diagnostic Delay: Because symptoms like stomach pain or fatigue are common in many conditions, it takes an average of 21 years from the start of symptoms to get a correct diagnosis [7][10].
  • Late-Onset Forms: Some people have a version of the disease that only affects one organ (like the heart) later in life, which can be easily missed or misdiagnosed [11][12].
  • Female Carriers: Fabry is an X-linked disorder, meaning the gene is on the X chromosome [4]. While it was once thought women were only “carriers” who didn’t get sick, we now know women can have symptoms ranging from mild to severe [13][11].

Because it is so rare, many local doctors may have never treated a patient with Fabry disease before [10]. This makes it essential to work with a specialized team that understands the condition [6].

Three Stabilizing Facts

If you are newly diagnosed, these three facts are the foundation for your journey forward:

  1. Treatment Exists: Unlike many rare genetic disorders, there are specific, FDA-approved treatments for Fabry disease, including Enzyme Replacement Therapy (ERT) and oral chaperone therapy [14][15].
  2. Early Action Matters: Starting treatment early can stabilize or slow down damage to your heart and kidneys, significantly improving long-term health and quality of life [14][16].
  3. Life Expectancy is Improving: While untreated Fabry disease can reduce life expectancy by 10 to 20 years, modern management and early intervention are designed to close that gap and protect your future [8][15].

The Path Ahead: Managed vs. Unmanaged

The “natural history” of the disease—what happens if it isn’t treated—usually involves a slow progression of organ damage [1].

  • Unmanaged: Without treatment, the continuous buildup of fatty substances often leads to kidney failure, heart disease (such as an enlarged heart), or an increased risk of stroke in early-to-mid adulthood [8][9].
  • Managed: When managed by a multidisciplinary team (specialists like cardiologists, nephrologists, and geneticists), the goal is to stop the buildup [6]. Regular monitoring and appropriate therapy can prevent irreversible organ damage and help you maintain an active life [14][17].

While there is still much to learn about why some people have more severe symptoms than others with the same genetic mutation, the most important step you have already taken is getting a diagnosis [18][19]. Knowledge is the first tool in protecting your health.

Frequently Asked Questions

What is Fabry disease?
Fabry disease is a rare genetic disorder where the body lacks a properly working enzyme called alpha-galactosidase A. Without this enzyme, a fatty substance called LysoGb3 builds up in your cells, which can eventually cause stress and damage to vital organs like the heart and kidneys.
Why does it take so long to get a Fabry disease diagnosis?
The symptoms of Fabry disease, such as fatigue, stomach pain, and burning in the hands and feet, are common in many other conditions. Because the disease is so rare, many doctors may not immediately suspect it, which leads to an average diagnostic delay of 21 years.
Can women get Fabry disease?
Yes. While it was historically believed that women were only carriers of the Fabry gene who didn't get sick, it is now known that women can experience symptoms ranging from mild to severe and require active monitoring and treatment.
Are there treatments available for Fabry disease?
Yes, there are specific, FDA-approved treatments available. Depending on your specific gene mutation, treatments may include intravenous Enzyme Replacement Therapy (ERT) or oral chaperone therapy. These treatments aim to stop the buildup of fatty substances and prevent organ damage.
What should I ask my doctor after being diagnosed with Fabry disease?
You should ask about your specific GLA gene mutation, your current enzyme activity levels, and whether your symptoms match your disease stage. It is also crucial to request a referral to a specialized multidisciplinary center that has dedicated experience treating Fabry disease.

Questions for Your Doctor

  • • What is the specific mutation (genotype) in my/my child's GLA gene, and is it considered 'classic' or 'late-onset'?
  • • How much alpha-galactosidase A enzyme activity was measured in the blood?
  • • Are my/my child's current symptoms (like pain or GI issues) typical for this stage of Fabry disease?
  • • Is my/my child's mutation 'amenable' to oral chaperone therapy, or is IV enzyme replacement therapy the standard first step?
  • • Can you refer us to a specialist or a multidisciplinary center that has experience specifically with Fabry disease?

Questions for You

  • • When did symptoms (like burning pain in hands/feet or lack of sweating) first appear, and what makes them worse?
  • • Are there other family members who have had unexplained kidney, heart, or hearing issues?
  • • How am I feeling emotionally after this diagnosis, and what kind of support (counseling, patient groups) do I need right now?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Current and Emerging Therapies for Lysosomal Storage Disorders.

    Abelleyra Lastoria DA, Keynes S, Hughes D

    Drugs 2025; (85(2)):171-192 doi:10.1007/s40265-025-02145-5.

    PMID: 39826077
  2. 2

    Lysosomal storage disorders: pathology within the lysosome and beyond.

    Kielian T

    Journal of neurochemistry 2019; (148(5)):568-572 doi:10.1111/jnc.14672.

    PMID: 30697734
  3. 3

    Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.

    Li W, Cologna SM

    Molecular omics 2022; (18(4)):256-278 doi:10.1039/d2mo00004k.

    PMID: 35343995
  4. 4

    Induced pluripotent stem cell line (INSAi002-A) from a Fabry Disease patient hemizygote for the rare p.W287X mutation.

    Duarte AJ, Ribeiro D, Santos R, et al.

    Stem cell research 2020; (45()):101794 doi:10.1016/j.scr.2020.101794.

    PMID: 32388441
  5. 5

    Analysis of the Effect of Demographic Variables on Lysosomal Enzyme Activities in the Missouri Newborn Screening Program.

    Vermette L, Washburn J, Klug T

    International journal of neonatal screening 2025; (11(2)) doi:10.3390/ijns11020048.

    PMID: 40559185
  6. 6

    Multidisciplinary Care Model as a Center of Excellence for Fabry Disease: A Practical Guide to Diagnosis and Management by Clinical Specialty in South Korea.

    Lee SY, Kim IY, Ahn SH, et al.

    Journal of clinical medicine 2025; (14(13)) doi:10.3390/jcm14134400.

    PMID: 40648776
  7. 7

    Anderson-Fabry disease in heart failure.

    Akhtar MM, Elliott PM

    Biophysical reviews 2018; (10(4)):1107-1119 doi:10.1007/s12551-018-0432-5.

    PMID: 29909504
  8. 8

    [Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease].

    Kes VB, Cesarik M, Zavoreo I, et al.

    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 2014; (68(2)):223-32.

    PMID: 26012164
  9. 9

    Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.

    Choi JH, Lee BH, Heo SH, et al.

    Medicine 2017; (96(29)):e7387 doi:10.1097/MD.0000000000007387.

    PMID: 28723748
  10. 10

    Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.

    Caputo F, Lungaro L, Galdi A, et al.

    International journal of environmental research and public health 2021; (18(6)) doi:10.3390/ijerph18063320.

    PMID: 33807115
  11. 11

    Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation.

    Selthofer-Relatic K

    Case reports in cardiology 2018; (2018()):6131083 doi:10.1155/2018/6131083.

    PMID: 29755794
  12. 12

    Late-Onset Fabry Disease Affecting the Kidneys and Liver While Sparing the Heart: A Case Report.

    Alitter Q

    Cureus 2022; (14(11)):e30989 doi:10.7759/cureus.30989.

    PMID: 36475199
  13. 13

    Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.

    Rodríguez Doyágüez P, Furlano M, Ars Criach E, et al.

    Nefrologia 2023; (43 Suppl 2()):91-95 doi:10.1016/j.nefroe.2024.01.018.

    PMID: 38278716
  14. 14

    [The neurological manifestations of Fabry disease. A review].

    Firsov KV, Kotov AS

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(9)):98-105 doi:10.17116/jnevro20161169198-105.

    PMID: 27735906
  15. 15

    Anderson-Fabry Disease: From Endothelial Dysfunction to Emerging Therapies.

    Stamerra CA, Del Pinto R, di Giosia P, et al.

    Advances in pharmacological and pharmaceutical sciences 2021; (2021()):5548445 doi:10.1155/2021/5548445.

    PMID: 34095851
  16. 16

    Fabry disease cardiomyopathy: A state-of-the-art review.

    Pande S, Varzideh F, Gambardella J, et al.

    Progress in cardiovascular diseases 2025; (92()):43-65 doi:10.1016/j.pcad.2025.08.003.

    PMID: 40840785
  17. 17

    Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease.

    Oder D, Nordbeck P, Wanner C

    Nephron 2016; (134(1)):30-6 doi:10.1159/000448968.

    PMID: 27576727
  18. 18

    Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.

    Tuttolomondo A, Simonetta I, Duro G, et al.

    Oncotarget 2017; (8(37)):61415-61424 doi:10.18632/oncotarget.18250.

    PMID: 28977874
  19. 19

    New mutation in Fabry disease: c.448delG, first phenotypic description.

    Calabrese E, Rodriguez Botta G, Rosenfeld DP

    Molecular genetics and metabolism reports 2021; (27()):100708 doi:10.1016/j.ymgmr.2021.100708.

    PMID: 33732617

This page provides a general overview of Fabry disease for educational purposes and does not replace professional medical advice. Always consult your healthcare provider or a Fabry disease specialist for guidance on your specific diagnosis and care plan.

Stay up to date

Get notified when new research about Fabry disease is published.

No spam. Unsubscribe anytime.